179 related articles for article (PubMed ID: 19800376)
21. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats.
Dahan A; Hoffman A
Eur J Pharm Biopharm; 2007 Aug; 67(1):96-105. PubMed ID: 17329087
[TBL] [Abstract][Full Text] [Related]
22. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
[TBL] [Abstract][Full Text] [Related]
23. Buccal mucosa as a route for systemic drug delivery: a review.
Shojaei AH
J Pharm Pharm Sci; 1998; 1(1):15-30. PubMed ID: 10942969
[TBL] [Abstract][Full Text] [Related]
24. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
Sudhakar Y; Kuotsu K; Bandyopadhyay AK
J Control Release; 2006 Aug; 114(1):15-40. PubMed ID: 16828915
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption.
Rekha MR; Sharma CP
J Control Release; 2009 Apr; 135(2):144-51. PubMed ID: 19331862
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers.
Lindmark T; Nikkilä T; Artursson P
J Pharmacol Exp Ther; 1995 Nov; 275(2):958-64. PubMed ID: 7473188
[TBL] [Abstract][Full Text] [Related]
27. Oral delivery of siRNA and antisense oligonucleotides.
Akhtar S
J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
[TBL] [Abstract][Full Text] [Related]
28. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
29. Buccal drug delivery.
Smart JD
Expert Opin Drug Deliv; 2005 May; 2(3):507-17. PubMed ID: 16296771
[TBL] [Abstract][Full Text] [Related]
30. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.
Porter CJ; Trevaskis NL; Charman WN
Nat Rev Drug Discov; 2007 Mar; 6(3):231-48. PubMed ID: 17330072
[TBL] [Abstract][Full Text] [Related]
31. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
32. Enhancing oral absorption in animals.
Crowley PJ; Martini LG
Curr Opin Drug Discov Devel; 2001 Jan; 4(1):73-80. PubMed ID: 11727326
[TBL] [Abstract][Full Text] [Related]
33. Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET).
Walsh EG; Adamczyk BE; Chalasani KB; Maher S; O'Toole EB; Fox JS; Leonard TW; Brayden DJ
Ther Deliv; 2011 Dec; 2(12):1595-610. PubMed ID: 22833984
[TBL] [Abstract][Full Text] [Related]
34. Enhancing intestinal drug solubilisation using lipid-based delivery systems.
Porter CJ; Pouton CW; Cuine JF; Charman WN
Adv Drug Deliv Rev; 2008 Mar; 60(6):673-91. PubMed ID: 18155801
[TBL] [Abstract][Full Text] [Related]
35. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
36. Thiolated chitosan: development and in vitro evaluation of an oral delivery system for acyclovir.
Palmberger TF; Hombach J; Bernkop-Schnürch A
Int J Pharm; 2008 Feb; 348(1-2):54-60. PubMed ID: 17716840
[TBL] [Abstract][Full Text] [Related]
37. Intestinal permeation enhancers for oral peptide delivery.
Maher S; Mrsny RJ; Brayden DJ
Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):277-319. PubMed ID: 27320643
[TBL] [Abstract][Full Text] [Related]
38. [Optimization and evaluation of a new antischistosomal drug QH917 self-microemulsifying drug delivery system].
Zhang JY; Gan Y; Gan L; Zhu CL; Pan WS
Yao Xue Xue Bao; 2007 Apr; 42(4):434-9. PubMed ID: 17633215
[TBL] [Abstract][Full Text] [Related]
39. In vitro interactions between the oral absorption promoter, sodium caprate (C(10)) and S. typhimurium in rat intestinal ileal mucosae.
Cox AB; Rawlinson LA; Baird AW; Bzik V; Brayden DJ
Pharm Res; 2008 Jan; 25(1):114-22. PubMed ID: 17546408
[TBL] [Abstract][Full Text] [Related]
40. Safety concerns over the use of intestinal permeation enhancers: A mini-review.
McCartney F; Gleeson JP; Brayden DJ
Tissue Barriers; 2016; 4(2):e1176822. PubMed ID: 27358756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
